Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Antiviral medication has emerged as an important tool in the prevention of HIV infection. In this randomized, controlled trial, an injectable long-acting agent, cabotegravir, was found to be superior to daily oral tenofovir disoproxil fumarate–emtricitabine in preventing incident HIV infection in ci...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2021-08, Vol.385 (7), p.595-608 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Antiviral medication has emerged as an important tool in the prevention of HIV infection. In this randomized, controlled trial, an injectable long-acting agent, cabotegravir, was found to be superior to daily oral tenofovir disoproxil fumarate–emtricitabine in preventing incident HIV infection in cisgender men and transgender women who have sex with men. |
---|---|
ISSN: | 0028-4793 1533-4406 1533-4406 |
DOI: | 10.1056/NEJMoa2101016 |